Ralliant’s (RAL) Buy Rating Reaffirmed at Truist Financial

Truist Financial restated their buy rating on shares of Ralliant (NYSE:RAL) in a research note published on Friday,Benzinga reports. The brokerage currently has a $82.00 price target on the stock, up from their previous price target of $68.00.

Several other equities analysts have also commented on the company. Vertical Research lowered Ralliant from a “buy” rating to a “hold” rating and set a $65.00 price target on the stock. in a research note on Wednesday, May 27th. Wall Street Zen lowered shares of Ralliant from a “buy” rating to a “hold” rating in a research note on Sunday, July 26th. Citigroup increased their target price on shares of Ralliant from $70.00 to $81.00 and gave the stock a “buy” rating in a report on Monday, July 13th. Barclays raised their target price on shares of Ralliant from $52.00 to $67.00 and gave the company an “overweight” rating in a research report on Wednesday, May 13th. Finally, TD Cowen boosted their price target on shares of Ralliant from $55.00 to $70.00 and gave the company a “buy” rating in a report on Wednesday, May 20th. One analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $75.70.

Ralliant Trading Down 1.8%

RAL opened at $65.78 on Friday. The stock’s fifty day moving average is $67.20 and its two-hundred day moving average is $54.34. The company has a market capitalization of $7.36 billion and a P/E ratio of -6.06. Ralliant has a 52 week low of $37.27 and a 52 week high of $75.41. The company has a quick ratio of 1.05, a current ratio of 1.52 and a debt-to-equity ratio of 0.75.

Ralliant (NYSE:RAL) last issued its earnings results on Thursday, July 30th. The company reported $0.68 earnings per share for the quarter, beating analysts’ consensus estimates of $0.63 by $0.05. Ralliant had a positive return on equity of 14.97% and a negative net margin of 56.38%.The business had revenue of $567.80 million during the quarter. Ralliant has set its FY 2026 guidance at 2.760-2.900 EPS and its Q3 2026 guidance at 0.720-0.780 EPS. Analysts forecast that Ralliant will post 2.83 earnings per share for the current year.

Ralliant Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Tuesday, June 23rd. Stockholders of record on Monday, June 8th were given a $0.05 dividend. This represents a $0.20 annualized dividend and a dividend yield of 0.3%. The ex-dividend date of this dividend was Monday, June 8th. Ralliant’s payout ratio is presently -1.83%.

Institutional Investors Weigh In On Ralliant

A number of hedge funds have recently made changes to their positions in the stock. Phocas Financial Corp. raised its holdings in Ralliant by 81.2% in the fourth quarter. Phocas Financial Corp. now owns 157,116 shares of the company’s stock worth $7,999,000 after purchasing an additional 70,403 shares in the last quarter. Teacher Retirement System of Texas boosted its holdings in shares of Ralliant by 6.9% in the 4th quarter. Teacher Retirement System of Texas now owns 570,878 shares of the company’s stock valued at $29,063,000 after buying an additional 36,800 shares in the last quarter. Alpha Omega Wealth Management LLC boosted its holdings in shares of Ralliant by 615.8% in the 4th quarter. Alpha Omega Wealth Management LLC now owns 40,291 shares of the company’s stock valued at $2,051,000 after buying an additional 34,662 shares in the last quarter. Irenic Capital Management LP grew its position in shares of Ralliant by 424.1% in the 1st quarter. Irenic Capital Management LP now owns 1,740,218 shares of the company’s stock worth $72,376,000 after buying an additional 1,408,176 shares during the last quarter. Finally, Rokos Capital Management LLP purchased a new position in shares of Ralliant in the 1st quarter worth approximately $42,022,000.

Key Stories Impacting Ralliant

Here are the key news stories impacting Ralliant this week:

• Positive Sentiment: Quarterly results exceeded expectations: Ralliant reported second-quarter revenue of approximately $568 million, up 13% year over year, and adjusted EPS of $0.68 versus the $0.63 consensus estimate. Adjusted net earnings were $76 million, while net earnings were $57 million. Ralliant Reports Second Quarter 2026 Results and Raises Full Year Guidance
• Positive Sentiment: Full-year and third-quarter outlooks topped consensus: Ralliant guided third-quarter EPS to $0.72-$0.78 and revenue to $570 million-$590 million, above analyst estimates of $0.68 and $556.4 million, respectively. Full-year 2026 adjusted EPS guidance was raised to $2.76-$2.90 from an analyst consensus of $2.65, with revenue expected around $2.25 billion-$2.30 billion. Ralliant forecasts 2026 revenue and productivity savings
• Positive Sentiment: Cost-reduction efforts could support future margins: Ralliant’s enterprise productivity program is targeting $50 million-$60 million in annualized run-rate savings by 2028, providing a potential boost to earnings and cash flow.
• Positive Sentiment: Analysts raised targets: Citigroup increased its target to $82 and initiated a “buy” rating, Truist raised its target to $82 while reaffirming “buy,” and RBC lifted its target to $73 while maintaining a “sector perform” rating. These targets imply meaningful upside from the recent trading level. Benzinga analyst actions
• Neutral Sentiment: Trading volatility increased: RAL experienced a temporary limit-up/limit-down trading pause during the earnings session, signaling elevated short-term volatility rather than a fundamental change in the business.
• Negative Sentiment: Valuation and execution risks remain: Despite the adjusted earnings beat, investors may continue to focus on Ralliant’s reported profitability, integration or productivity-program execution, and the gap between the stock’s recent price and analyst targets.

About Ralliant

Ralliant, Inc (NYSE: RAL) is a medical technology company focused on enabling point-of-care cell therapy solutions in the field of regenerative medicine. The company develops and markets systems that isolate, concentrate and store adipose-derived stromal vascular fraction (SVF) cells directly from a patient’s own fat tissue, facilitating same-day, autologous treatments without the need for extensive laboratory infrastructure.

The company’s core product portfolio includes proprietary device platforms and single-use processing kits engineered to streamline the workflow for clinicians.